低剂量分次放疗增敏化疗治疗晚期结直肠癌的临床效果

Clinical Effects of Low-dose Fractionated Radiotherapy Sensitized Chemotherapy in Treating with Advanced Colorectal Cancer

目的:探讨对晚期结直肠癌患者采取低剂量分次放疗增敏化疗(LDFRT)治疗的有效性及可行性。方法:选取2017年3月—2019年3月广西科技大学第一附属医院肿瘤科经病理学或组织学确诊的40例晚期结直肠癌患者为研究对象,按照随机数字表法分为对照组和试验组,各20例。对照组给予常规化疗治疗,试验组在对照组基础上联合LDFRT治疗。比较两组近期疗效、不良反应、总生存期(OS)和无进展生存期(PFS)、免疫功能。结果:试验组客观缓解率高于对照组,差异有统计学意义(P=0.038);试验组中位OS、PFS长于对照组,差异有统计学意义(P<0.05);试验组、对照组不良反应发生率比较,差异无统计学意义(P>0.05);治疗后,试验组CD8+低于对照组,CD4+、CD4+/CD8+、中性粒细胞计数、淋巴细胞计数水平均高于对照组,差异有统计学意义(P<0.05)。结论:LDFRT治疗晚期结直肠癌患者效果较好,能延长患者无进展生存时间,增加患者免疫功能,不会增加不良反应。

Objective:To explore the effectiveness and feasibility of adopting low-dose fractionated radiotherapy sensitized chemo⁃therapy(LDFRT)treatment for patients with advanced colorectal cancer.Methods:Forty patients with advanced colorectal cancer diagnosed by pathology or histology in the Department of Oncology of the First Affiliated Hospital of Guangxi University of Science and Technology from March 2017 to March 2019 were selected as the study subjects,and were divided into the control group and the experimental group,each with twenty cases,according to the method of randomized numerical table.The control group was giv⁃en conventional chemotherapy treatment,and the experimental group was combined with LDFRT treatment on the basis of the con⁃trol group.Recent efficacy,adverse effects,overall survival(OS)and progression-free survival(PFS),and immune function were compared between the two groups.Results:The objective remission rate of the experimental group was higher than that of the con⁃trol group,and the difference was statistically significant(P=0.038);The median OS and PFS of the experimental group were lon⁃ger than those of the control group,and the difference was statistically significant(P<0.05);Comparison of the incidence of ad⁃verse reactions in the experimental and control groups,the difference was not statistically significant(P>0.05);After treatment,CD8+of the experimental group was lower than that of the control group,and the levels of CD4+,CD4+/CD8+,neutrophil count,and lymphocyte count were higher than those of the control group,with statistically significant differences(P<0.05).Conclusion:LDFRT is more effective in treating patients with advanced colorectal cancer,prolongs progression-free survival time,increases patients'immune function,and does not increase adverse reactions.